[Effect of the cannabinoid receptor ligand WIN-55,212-2 on the TNF-alpha production by human mononuclear cells].
Synthetic cannabinoid WIN-55,212-2 produces a dose-dependent decrease on the TNF-alpha production by LPS-stimulated human mononuclear cells in vitro. The most pronounced inhibition of the TNF-alpha synthesis was observed for a drug concentration of 10 microM.
Isachenko
E G
EG
Laboratory of Biomedical Research, Vladivostok Department of the Far-Eastern Scientific Center of Breathing Physiology and Pathology, Institute of Medical Climatology and Restorative Therapy, Siberian Division, Russian Academy of Medical Sciences, Russia.
Vitkina
T I
TI
Berdyshev
E V
EV
D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008024:Ligands; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D048588:Benzoxazines; D063386:Cannabinoid Receptor Agonists; D008024:Ligands; D009025:Morpholines; D009281:Naphthalenes; D014409:Tumor Necrosis Factor-alpha; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone